Abstract
Nanotechnology, or systems/devices manufactured at the molecular level, is a multidisciplinary scientific field undergoing explosive development. A part of this field is the development of nanoscaled drug delivery devices. Nanoparticles have been developed as an important strategy to deliver conventional drugs, recombinant proteins, vaccines and more recently nucleotides. Nanoparticles and other colloidal drug delivery systems modify the kinetics, body distribution and drug release of an associated drug. Other effects are tissue or cell specific targeting of drugs and the reduction of unwanted side effects by a controlled release. Therefore nanoparticles in the pharmaceutical biotechnology sector improve the therapeutic index and provide solutions for future delivery problems for new classes of so called biotech drugs including recombinant proteins and oligonucleotides. This review discusses nanoparticular drug carrier systems with the exception of liposomes used today, and what the potential and limitations of nanoparticles in the field of pharmaceutical biotechnology are.
Keywords: Nanobiotechnology, liposomes, nanoscaled drug
Current Pharmaceutical Biotechnology
Title: The Impact of Nanobiotechnology on the Development of New Drug Delivery Systems
Volume: 6 Issue: 1
Author(s): O. Kayser, A. Lemke and N. Hernandez-Trejo
Affiliation:
Keywords: Nanobiotechnology, liposomes, nanoscaled drug
Abstract: Nanotechnology, or systems/devices manufactured at the molecular level, is a multidisciplinary scientific field undergoing explosive development. A part of this field is the development of nanoscaled drug delivery devices. Nanoparticles have been developed as an important strategy to deliver conventional drugs, recombinant proteins, vaccines and more recently nucleotides. Nanoparticles and other colloidal drug delivery systems modify the kinetics, body distribution and drug release of an associated drug. Other effects are tissue or cell specific targeting of drugs and the reduction of unwanted side effects by a controlled release. Therefore nanoparticles in the pharmaceutical biotechnology sector improve the therapeutic index and provide solutions for future delivery problems for new classes of so called biotech drugs including recombinant proteins and oligonucleotides. This review discusses nanoparticular drug carrier systems with the exception of liposomes used today, and what the potential and limitations of nanoparticles in the field of pharmaceutical biotechnology are.
Export Options
About this article
Cite this article as:
Kayser O., Lemke A. and Hernandez-Trejo N., The Impact of Nanobiotechnology on the Development of New Drug Delivery Systems, Current Pharmaceutical Biotechnology 2005; 6 (1) . https://dx.doi.org/10.2174/1389201053167158
DOI https://dx.doi.org/10.2174/1389201053167158 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Cell-based Assays for Assessing Toxicity: A Basic Guide
Medicinal Chemistry Plasma-Free Amino Acid Profiling of Nasal Polyposis Patients
Combinatorial Chemistry & High Throughput Screening Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives
Current Molecular Medicine Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics Cognitive Function and Quality of Life in Mild Thyroid Hormone Deficiency
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Acetylation Control of Cancer Cell Metabolism
Current Pharmaceutical Design Review on Oxford Textbook of Oncology. 3rd Edition, 2016
Recent Patents on Anti-Cancer Drug Discovery The Emerging Roles of RASSF5 in Human Malignancy
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy of Cancer with Interleukin-12
Current Pharmaceutical Design State of the Art on Carbonic Anhydrase Modulators for Biomedical Purposes
Current Medicinal Chemistry Transcatheter Embolization Therapy in Liver Cancer
Recent Patents on Medical Imaging The Role of miRNAs in the Differentiation of Adipose-Derived Stem Cells
Current Stem Cell Research & Therapy Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Mucosal Vaccine Vectors: Replication-Competent Versus Replication-Deficient Poxviruses
Current Pharmaceutical Design Mitochondrial Signaling and Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Implications
Current Pharmaceutical Design Matrix Metalloproteinases in Respiratory Diseases: From Pathogenesis to Potential Clinical Implications
Current Medicinal Chemistry Potential Interactions of Carotenoids with Other Bioactive Food Components in the Prevention of Chronic Diseases
Current Bioactive Compounds Integrating Care for Older Adults with Cognitive Impairment
Current Alzheimer Research